It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SBFM’s FA Score shows that 0 FA rating(s) are green whileTXMD’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SBFM’s TA Score shows that 4 TA indicator(s) are bullish while TXMD’s TA Score has 4 bullish TA indicator(s).
SBFM (@Pharmaceuticals: Other) experienced а -5.19% price change this week, while TXMD (@Pharmaceuticals: Other) price change was -9.52% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.61%. For the same industry, the average monthly price growth was +1.68%, and the average quarterly price growth was -9.09%.
SBFM is expected to report earnings on Jul 31, 2024.
TXMD is expected to report earnings on Feb 20, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
SBFM | TXMD | SBFM / TXMD | |
Capitalization | 6.02M | 24.3M | 25% |
EBITDA | -26.1M | 52.6M | -50% |
Gain YTD | -99.495 | -49.333 | 202% |
P/E Ratio | 0.88 | 0.47 | 185% |
Revenue | 20.4M | 69.4M | 29% |
Total Cash | 18.8M | 10.2M | 184% |
Total Debt | 674K | 8.2M | 8% |
SBFM | TXMD | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 53 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 41 Fair valued | 46 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 92 | |
PRICE GROWTH RATING 1..100 | 65 | 89 | |
P/E GROWTH RATING 1..100 | 90 | 100 | |
SEASONALITY SCORE 1..100 | 95 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SBFM's Valuation (41) in the null industry is in the same range as TXMD (46) in the Pharmaceuticals Generic industry. This means that SBFM’s stock grew similarly to TXMD’s over the last 12 months.
SBFM's Profit vs Risk Rating (100) in the null industry is in the same range as TXMD (100) in the Pharmaceuticals Generic industry. This means that SBFM’s stock grew similarly to TXMD’s over the last 12 months.
TXMD's SMR Rating (92) in the Pharmaceuticals Generic industry is in the same range as SBFM (94) in the null industry. This means that TXMD’s stock grew similarly to SBFM’s over the last 12 months.
SBFM's Price Growth Rating (65) in the null industry is in the same range as TXMD (89) in the Pharmaceuticals Generic industry. This means that SBFM’s stock grew similarly to TXMD’s over the last 12 months.
SBFM's P/E Growth Rating (90) in the null industry is in the same range as TXMD (100) in the Pharmaceuticals Generic industry. This means that SBFM’s stock grew similarly to TXMD’s over the last 12 months.
SBFM | TXMD | |
---|---|---|
RSI ODDS (%) | 2 days ago79% | 2 days ago81% |
Stochastic ODDS (%) | 2 days ago78% | 2 days ago73% |
Momentum ODDS (%) | 2 days ago90% | 2 days ago87% |
MACD ODDS (%) | 2 days ago90% | 2 days ago85% |
TrendWeek ODDS (%) | 2 days ago90% | 2 days ago87% |
TrendMonth ODDS (%) | 2 days ago81% | 2 days ago85% |
Advances ODDS (%) | 13 days ago83% | 20 days ago69% |
Declines ODDS (%) | 9 days ago90% | 2 days ago89% |
BollingerBands ODDS (%) | 2 days ago90% | 2 days ago74% |
Aroon ODDS (%) | 2 days ago90% | 2 days ago86% |
A.I.dvisor tells us that SBFM and AKAN have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SBFM and AKAN's prices will move in lockstep.
Ticker / NAME | Correlation To SBFM | 1D Price Change % | ||
---|---|---|---|---|
SBFM | 100% | +0.74% | ||
AKAN - SBFM | 22% Poorly correlated | +1.48% | ||
TXMD - SBFM | 22% Poorly correlated | -3.39% | ||
EVOK - SBFM | 22% Poorly correlated | +0.03% | ||
SUPN - SBFM | 22% Poorly correlated | -0.74% | ||
SIGA - SBFM | 21% Poorly correlated | -1.46% | ||
More |
A.I.dvisor indicates that over the last year, TXMD has been loosely correlated with LIEN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if TXMD jumps, then LIEN could also see price increases.
Ticker / NAME | Correlation To TXMD | 1D Price Change % | ||
---|---|---|---|---|
TXMD | 100% | -3.39% | ||
LIEN - TXMD | 36% Loosely correlated | -0.04% | ||
DRRX - TXMD | 32% Poorly correlated | -3.96% | ||
ASRT - TXMD | 27% Poorly correlated | -1.55% | ||
ACB - TXMD | 23% Poorly correlated | +4.20% | ||
CTLT - TXMD | 23% Poorly correlated | N/A | ||
More |